Weimin Wang is the Founder and CEO of Sanegene Bio, a company focused on innovative RNA-based therapeutics. Recognized as a pioneer in oligonucleotide chemistry, his career of over two decades includes key leadership roles at Dicerna Pharmaceuticals, Merck, and Sirna Therapeutics, where he advanced novel RNAi drug development.
There is no publicly available information regarding Weimin Wangs personal life or hobbies.
He is a key inventor of the innovative GalXC™ and GalXC-Plus™ RNAi delivery technologies and is named on over 70 scientific papers and patents.
Weimin Wang
Founder, Chief Executive Officer at Sanegene Bio
Watertown, Massachusetts, United States
Overview
Topics They Care About
RNAi Therapeutics
A leader in the field for over 20 years, he has contributed to impactful RNAi medicines and founded Sanegene Bio to focus on this modality.
Drug Delivery Platforms
He was a key inventor of Dicerna's GalXC™ delivery technology and developed one of the first lipid nanoparticle delivery systems at Merck/Sirna.
Biotech Entrepreneurship
As the Founder and CEO of Sanegene Bio, he leads the company's strategy, financing, and partnerships to advance its pipeline of genetic medicines.
Media Appearances
Weimin has no verified media appearances
Work History
2-2021
Founder, Chief Executive Officer at Sanegene Bio
6-2019 - 1-2021
Executive Director at Dicerna Pharmaceuticals, Inc.
1-2014 - 6-2019
Senior Director at Dicerna Pharmaceuticals, Inc.
12-2006 - 12-2013
Research Fellow at Merck
11-1999 - 12-2006
Senior Scientist at Sirna Therapeutics
Education
BS from Peking University
Doctor of Philosophy (Ph.D.) from Rutgers University
More Information
Social Presence :
Prographics :
Exp : 26
Location : Watertown, Massachusetts, United States
Job Level : Leadership
Designation : Founder, Chief Executive Officer at Sanegene Bio
